Published in Gene Therapy Weekly, January 20th, 2005
The NIAID/NIH award for $993,771 will be used to screen the genomes of variola (smallpox) and vaccinia (cowpox) for common elements, also known as epitopes that drive protective immunity. However, EpiVax researchers will not be using the actual smallpox virus in conducting their research.
Having successfully proven that EpiVax can accurately identify...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.